Loading...
•
Mar 31, 2023
Corcept Therapeutics Q1 2023 Earnings Report
Announced first quarter financial results and provided corporate update.
Key Takeaways
Corcept Therapeutics reported Q1 2023 revenue of $105.7 million, compared to $93.7 million in Q1 2022. Net income was $15.9 million, or $0.14 per share diluted, compared to $22.8 million, or $0.20 per share diluted, in the same period last year. The company raised its 2023 revenue guidance to $435 - $455 million.
Revenue of $105.7 million, compared to $93.7 million in first quarter 2022
Raised 2023 revenue guidance to $435 – $455 million, from $430 – $450 million
Net income per common share of $0.14 (diluted), compared to $0.20 in first quarter 2022
Cash and investments of $465.1 million as of March 31, 2023
Forward Guidance
Corcept raised its 2023 revenue guidance to $435 - $455 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...